Letters, Statements & Analysis

As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.

Yesterday, the Senate Health, Education, Labor, and Pensions (HELP) Committee released the text and a section-by-section summary of its portion of the reconciliation bill. The package focuses largely on higher education, targeting financial assistance programs that Republicans allege inflate tuition costs at colleges and universities. While the committee adjusted certain policies in the One Big, Beautiful Bill Act (H.R. 1), the House’s version of reconciliation that passed last month, the draft bill leaves two policies that AMCP is tracking untouched.

State legislatures across the country have introduced bills designed to regulate the use of artificial intelligence (AI) systems by health care entities.

Today, the Congressional Budget Office (CBO) released an updated cost estimate for the One Big, Beautiful Bill Act (H.R. 1). This cost estimate incorporates the amendments made to H.R. 1 in the hours before the House passed the legislation by a vote of 215-214-1.

Academy of Managed Care Pharmacy (AMCP) issued a statement from CEO Susan A. Cantrell, MHL, RPh, CAE, following passage of the budget reconciliation bill that includes large-scale changes to Medicaid, the Affordable Care Act (ACA), Grad PLUS loans, and other programs.

Under the budget resolution adopted on April 10, 2025, the House Energy & Commerce Committee (E&C) is required to submit changes in laws under its jurisdiction to reduce the deficit by at least $880 billion over the fiscal years (FY) 2025-2034.

A coalition of 34 scientific and medical organizations led by the American Association of Immunologists and the American College of Physicians released the following statement.

The Protecting Pharmacies in Medicaid Act would prohibit the use of spread pricing arrangements in Medicaid programs. Pharmacy benefit managers (PBMs) would be required to pass through to pharmacies the full amount of the money paid to the PBMs by Medicaid programs, except for a fixed administrative fee. The total reimbursement amount will be determined by a survey of national average drug acquisition costs administered by the Department of Health & Human Services.

Over the weekend, Congressional leadership released a continuing resolution (CR) that extends government funding at the same level as the previous fiscal year, through September 30. Congress must extend government funding by March 14 to avoid a government shutdown.

In AMCP's latest comments to the FDA, we emphasize the need for standardized public reporting of confirmatory trial progress, ensuring payers and health care providers have the necessary data to make informed coverage decisions. By supporting proactive communication and rigorous confirmatory trials, AMCP aims to balance early access to innovative treatments with patient safety and long-term therapeutic value.